Benchmarking blood donor safety practices: a first experience

Gilles Folléa¹, Pierre Tiberghien²

¹- European Blood Alliance, Brussels, Belgium  g.follea@sanquin.nl
²- Etablissement Français du Sang, Saint Denis, France  pierre.tiberghien@efs.sante.fr

16th International Haemovigilance Seminar
Barcelona, March 5, 2014
Background and objectives

Background: blood donor safety

- Major importance
- Assessment in scientific studies: recent
- Important variations in practices still persist.

Objectives

- To **benchmark donor safety practices** implemented at EFS, with help from international experts
- To **identify ways of improvement**
  - for EFS
  - and other blood establishments of EBA.
Member (Dormant)

1. Austria
2. Belgium - 2
3. Croatia
4. (Czech Republic)
5. (Cyprus)
6. Denmark
7. Estonia
8. Finland
9. France
10. Germany - 2
11. (Greece)
12. Hungary
13. Iceland
14. Ireland
15. Italy
16. Latvia
17. Lithuania
18. Luxembourg
19. Malta
20. The Netherlands
21. Norway
22. Portugal
23. Romania
24. Slovenia
25. Spain
26. Sweden
27. Switzerland
28. United Kingdom - 4

Population: 450 M
Blood donations: 18 M
2012:
- 3.1 million blood donations
- 1.7 million blood donors of which 360,000 first-time donors
- 153 blood centers, 40,000 mobile blood collection operations
- 9,800 employees
- A budget of €846 million
L’EFS: the only transfusion establishment in France:

- Risk for emulation, constructive criticism and innovation
- Professional expertise seldomly present outside of the EFS
- Expert transfusion « regulators »: most often trained at the EFS
- Insufficient outreach towards «non-french » transfusion experts by our regulators and health authorities

**Maybe are we not that good!?**

**Emulation** (Webster) : ambition or endeavor to equal or excel others
Benchmarking: definition and process
(N. Heddle, 2013)

Definition
“A structured, continuous, collaborative process in which comparisons for selected indicators are used to identify factors which when implemented will improve transfusion practices”.

Benchmarking process components
1. **Comparisons** between institutions to identify practice variation;
2. Communication and/or evaluation process to **identify** factors associated with **best practices**;
3. **Introduce** best practice factors into one’s own setting;
Methodology and Main Outcomes
Material and Methods

• Voluntary basis: request from EFS to EBA
• Joint EFS – EBA Meeting / Paris, 20 – 21 June 2013
• EFS presentation to 4 experts (DE, FI, NL, UK):
  – D1: Visit of blood collection site
  – D2: Workshop with presentation by EFS of all available data as to means and results with regard:
    • to preventing adverse donor reactions
    • curing / managing donors with adverse reactions
    • donor vigilance
• Discussion with EFS managers involved in donor safety.
• EBA - facilitated identification of best practices and ways for improvement of donor safety.
• Identification of strengths, weaknesses and actions review approved by all participants.
Specifics
Whole blood donation volumes

Practice variation

- **EU Regulation**: 450 +/- 50mL
- **FR, UK**: donors deferred if planned collected volume exceeds 15% of blood volume (BV)
- This limitation is apparently not always implemented elsewhere.

Good Practice (GP) recommended

- Blood establishments (BE) not doing so yet should implement CoE Guide recommendations: “Because of risk of adverse reactions, no more than 15% of estimated BV should be collected. In case of women weighing < 65 kg and donating a total > 485 mL (450 + 35 mL for testing), the blood volume should be calculated.”
Calculated minimum blood volume of a female donor donating 485, 510, or 535 mL  

<table>
<thead>
<tr>
<th>Volume of blood to be collected</th>
<th>Maximum percentage of blood volume collected</th>
<th>Minimum acceptable blood volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>450 mL + 35 mL</td>
<td>15%</td>
<td>3,233 mL</td>
</tr>
<tr>
<td>475 mL + 35 mL</td>
<td>15%</td>
<td>3,400 mL</td>
</tr>
<tr>
<td>500 mL + 35 mL</td>
<td>15%</td>
<td>3,567 mL</td>
</tr>
</tbody>
</table>

- Men weighing ≥ 50 kg have a sufficiently large BV to donate a total 535 mL (500 + 35)
- Women weighing ≥ 50 kg have a sufficiently large BV to donate a total 485 mL (450 + 35)
Hemoglobin measurement and levels

Practice variation

− **EU Reg:** Hb in donor's blood ≥ 125 g/L (F); ≥ 135 g/L (M)

− **France** (based on Lotfi 2005 and Ziemann 2006 studies)
  • Pre-donation Hb screening: new & returning donors, donors with <125 g/L (F); < 135 g/L (M) at previous donation blood count
  • Blood count performed at each donation
  • No Hb screening if ≥ 125 g/L (F); ≥ 135 g/L (M) at previous donation

− **Other countries:** pre-donation Hb screening in all donors.

Conclusion/action

EFS encouraged to submit its experience for publication in a peer reviewed journal, with regard to donor safety (and in the perspective of a possible EU blood directive revision).
## Prevention of Vasovagal reactions

EFS Data, 2012
3,1 million blood donations

### Incidence per 100 000 donations

<table>
<thead>
<tr>
<th>Immediate vasovagal reactions</th>
<th>99,9</th>
<th>Delayed vasovagal reactions</th>
<th>12,1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole Blood</td>
<td>101,2</td>
<td>Whole Blood</td>
<td>12,0</td>
</tr>
<tr>
<td>Apheresis</td>
<td>93,0</td>
<td>Apheresis</td>
<td>12,8</td>
</tr>
<tr>
<td>Donor 18&lt;=30 years old</td>
<td>191,0</td>
<td>Donor 18&lt;=30 years old</td>
<td>13,9</td>
</tr>
<tr>
<td>Donor &gt; 30 years old</td>
<td>28,4</td>
<td>Donor &gt; 30 years old</td>
<td>7,5</td>
</tr>
<tr>
<td>Male donors</td>
<td>85,1</td>
<td>Male donors</td>
<td>3,6</td>
</tr>
<tr>
<td>Female donors</td>
<td>117,4</td>
<td>Female donors</td>
<td>22,2</td>
</tr>
<tr>
<td>New</td>
<td>288,4</td>
<td>New</td>
<td>18,8</td>
</tr>
<tr>
<td>Repeat</td>
<td>68,2</td>
<td>Repeat</td>
<td>11,0</td>
</tr>
</tbody>
</table>
Prevention of Vasovagal reactions

Practice variation

- **EU Regulation**: no requirement
- **FR**: donor hydration is set up; muscle tension not encouraged
- **Other countries**: donor hydration set up and muscle tension encouraged.

GP recommendation

- Donor hydration and muscle tension to be considered as GP
- EFS encouraged to reorganize the post-donation resting areas to insure facial contact between donors and staff
- EFS encouraged not to wait too long to perform its study on effectiveness of isotonic hydration and muscle tension.

“Evasion” study: randomized clinical trial evaluating the impact of isotonic hydration and/or muscle tension on the frequency and severity of vasovagal reactions in 4500 whole blood donors
Prevention of cardiovascular decompensation

Practice variation

- EU Regulation:
  - Prospective donors with active or past serious CV disease: permanent deferral
  - Blood pressure (BP), pulse rate (PR): no requirement
- FR, DE, NL: BP and PR measured before each donation
- FI, UK: BP and PR not measured in blood donors

Conclusion/action

- Studies needed to assess potential value of BP and PR for donor safety
- FR requested to make its SOP available for all other criteria implemented for preventing this type of risk.
Qualification required for pre-donation interview

Practice variation
- **EU Regulation:** interview by a qualified healthcare professional
- **FR, DE:** interview must be carried out by a MD
- **FI and UK:** interviews carried out by non-MDs (MD on call).
- **NL:** MD for new and returning donors, non-MDs for regular donors, MD on site.

Conclusion/action
- Impossible to objectively identify GP for pre-donation interviewer qualification (MD or not).
- EFS to pursue its project to introduce qualified nurses for pre-donation interviews and publish its experience.
Staff training and qualification

EFS practice
- Training procedure
- Staff qualification
- Staff assessment after re-training: maintain, upgrade or downgrade qualification.

Conclusion/action
- EFS practice appreciated by the international experts
- EFS requested to make available to other BEs its staff training and qualification procedures (available in english).
Self-assessment system to reduce risks

EFS practice

Risk analysis

- Identification of essential security features
- Internal standard redaction and/or audit guide
- Self-assessment implementation
- Verification by audit

Internal accreditation / Enabling
Self-assessment system to reduce risks

EFS practice

1- Internal **standard** established on the basis of essential security feature identified

2- **Self-assessment guide** established on:
   - what is expected regarding the internal standard
   - a scoring system

3- A technical committee in charge of:
   - analyzing and evaluating all results and actions plan regarding safety aspect
     - recommending actions
     - concluding about eligibility
   - appointing audits on specific sites
Self-assessment system to reduce risks

- Since 2011, all 252 sites are eligible under our habilitation system for apheresis and whole blood collection
- In 2013, extension of habilitation system to therapeutic apheresis and granulocytes collection

Conclusion/action
- EFS practice appreciated by the international experts
- EFS encouraged to publish its experience and to further assess and validate the method in a second country.
Donor vigilance to monitor/assess donor adverse events ("near misses") and reactions

Practices: globally equivalent in all 5 countries

- Rates of severe adverse reactions in donors roughly comparable
- All significant SARD and SAE quickly reported to BE board staff and discussed at national level
- Difficulties for benchmarking practices and deducing donor safety measures from current vigilance data.

GP recommendations

- Regular discussion on donor safety issues at national level should be encouraged as GP
- Need to improve capacity to deduce donor safety measures from vigilance data
Post-workshop follow up: current status
Whole blood donation volumes

Practice variation

- **EU Regulation**: 450 +/- 50mL
- **FR, UK**: donors deferred if collected volume would exceed 15 % of blood volume (BV)
- This limitation is apparently not always implemented elsewhere.

GP recommendation:

BEs not doing so yet should implement CoE Guide recommendations: “Because of risk of adverse reactions, no more than 15 % of estimated BV should be collected. In case of **women weighing < 65 kg** and donating a total > 485 mL (**450 + 35 mL for testing**), the blood volume should be calculated.”
Hemoglobin measurement and levels

Practice variation

- **EU Reg:** Hb in donor's blood $\geq 125$ g/L (F); $\geq 135$ g/L (M)
- **FR** (based on Lotfi 2005 and Ziemann 2006 studies)
  - Pre-donation Hb screening: new & returning donors, donors with $<125$ g/L (F); $<135$ g/L (M) at previous donation blood count
  - Blood count performed at each donation
  - No Hb screening if $\geq 125$ g/L (F); $\geq 135$ g/L (M) at previous donation
- Other countries: pre-D. Hb screening in all donors.

collection/action

EFS encouraged to submit its experience for publication in a peer reviewed journal, with regard to donor safety (and in perspective of EU blood directive revision).
Prevention of Vasovagal reactions

Practice variation

- EU Regulation: no requirement
- FR: donor hydration is set up; muscle tension not encouraged.
- Other countries: donor hydration set up and muscle tension encouraged.

GP recommendation
- Donor hydration and muscle tension to be considered as GP
- EFS encouraged to reorganize the post-donation rest areas to insure facial contact between donors and staff.
- EFS encouraged not to wait too long to perform its study on effectivity of isotonic hydration and muscle tension.

"Evasion" study: randomized clinical trial evaluating the impact of isotonic hydration and muscle tension.

Post-donation rest areas will be adapted

2000 donors included as proof of concept 2014.

When needed study underway, expected 2014.
Prevention of cardiovascular decompensation

Practice variation

- EU Regulation:
  - Prospective donors with active or past serious CV disease: permanent deferral
  - Blood pressure (BP), pulse rate (PR): no requirement
- FR, DE, NL: BP and PR measured before each donation
- FI, UK: BP and PR not measured in blood donors

Conclusion/action

- Studies needed to assess potential value of BP and PR for donor safety
- FR requested to make its SOP available for all other criteria implemented for preventing this type of risk.

SOP in english being prepared
Qualification required for pre-donation interview

Practice variation

• EU Regulation: interview by a qualified healthcare professional
• FR, DE: interview must be carried out by a MD
• FI and UK: interviews carried out by non-MDs (MD on call)
• NL: MD for new and returning donors, non-MD for regular donors

Conclusion/action

‒ Impossible to objectively identify GP for pre-donation interviewer qualification (MD or not).
‒ EFS to pursue its project to introduce qualified nurses for pre-donation interviews and publish its experience.

Large scale experimentation to evaluate feasibility and safety of pre-donation interviews by nurses scheduled to be initiated in 2014.
Staff training and qualification

EFS practice
- Training procedure
- Staff qualification
- Staff assessment after re-training: maintain, upgrade or downgrade qualification.

Conclusion/action
- EFS practice appreciated by the international experts
- EFS requested to make available to other BEs its staff training and qualification procedures (available in EN).
Self-assessment system to reduce risks

Conclusion/action
- EFS practice appreciated by the international experts
- EFS encouraged to publish its experience and to further assess and validate the method in a second country.
Donor vigilance to monitor/assess donor adverse events ("near misses")

Practices: globally equivalent
- Rates of severe adverse reactions in donors roughly comparable
- All significant severe adverse reactions (SARD and SAE) quickly reported to BE board staff and discussed at national level
- Difficulties for benchmarking practices and deducing donor safety measures from current vigilance data

GP recommendations
- Regular discussion on donor safety issues at national level should be encouraged as GP
- Need to improve capacity to deduce donor safety measures from vigilance data

For all of us!
Conclusions
• The international experts appreciated the efforts of EFS and the method used for this meeting.

• The benchmarking method set up for this meeting on donor safety proved to be effective in identifying practice variation and for a number of items good (best) practice.

• They expressed confidence in the system and measures implemented by EFS for donor safety.

• A follow up of the meeting outcomes will be organized to assess if this benchmarking exercise succeeded in inducing changes in practices, and beyond in improving donor safety.
Benchmarking donor safety practices: lessons drawn

- **Added value, helped identifying:**
  - GPs for medical points (blood donation volumes, muscle tension) and organisational points (staff training and qualification);
  - Domains for which GPs cannot be identified, needing (further) studies (Hb screening, qualification for pre-donation interview).
  - Potentially helpful for regulation revisions

- **Feasibility, acceptability**
  - Based on a careful preparation (neither inspection, nor audit)
  - All participants positively involved

- **Ways for improvement**
  - Completing the benchmarking cycle
Current limitations of donor vigilance

- Definitions
  - Universally accepted definitions still missing despite huge efforts

- Denominators
  - Sometimes questionable or even missing (e.g., units distributed vs transfused)

- Distance between vigilance data and safety practices

→ Capacity of haemovigilance to bring measures to improve donor (and patient) safety?

→ Benchmarking safety practices: a desirable complement to haemovigilance?
Annual EU reporting of serious adverse reactions for blood & BCs (2011): haemovigilance limitations

- Anaphylaxis/hypersensitivity: 46.89%
- TRALI: 4.19%
- Post-transfusion purpura: 0.38%
- Graft versus host disease: 0.06%
- Other: 3.37%
- FNHTR: 17.09%
- Respiratory disorders, other than TRALI: 2.54%
- TACO: 9.72%
- TAD: 4.45%
- Non-immunological haemolysis: 1.02%
- Immunological haemolysis: 9.02%
- Transfusion-transmitted infection: 1.27%
Conclusions, ways forward

– Benchmarking donor safety practice
  • An effective method to identify good practices and also domains needing further studies to do so.
  • Subject to careful review of practices, collaboration with international experts, and completion of benchmarking cycle.

– Towards a more effective role of donor vigilance to continuously improve donor safety?
  • Prioritising practices to benchmark
  • Re-assessing impact after implementation

– Applicability to patient haemovigilance? To be evaluated.
Acknowledgements

European experts

– Wim de Kort, Sanquin, Netherlands
– Gail Miflin, NHSBT, United Kingdom
– Johanna Castrén, RFCBS, Finland
– Harald Klüter, ITMI, Germany

EFS experts

– Djamel Benobar
– Françoise Maire
– Bruno Danic
– Geneviève Woimant
– Chantal Jacquot
– Saadia Jbilou
– Stéphanie Julien
– Bertrand Pelletier
– Nicole Coudurier
– Yves Charpak
– Rachid Djoudi
Thank you for your attention!

Questions, comments?